CD56+CD16+ NK cells were elevated in autoimmune and pembrolizumab-induced thyroiditis patients, while immature CD56brCD16− NK cells were decreased in pembrolizumab-induced thyroiditis patients and elevated in autoimmune patients. This evidence concerns the gene NCAM1 and thyroid gland disorder.